Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

	Under the Paperwor	k Reduc	tion Act of 1995, no persons	are required to respond to a collection of	of information unless it contains a	valid DMB	control m	P.
Substitute	for form 1449A/PTC	·			C mplete if Kn wn	오		為
				Application Number	10/049,464	C	36	
INFO	RMATION	DIS	CLOSURE	Filing Date	6/18/2002	2	-0	ロ
STAT	EMENT B	Y AI	PPLICANT	First Named Inventor	HUENIG	而	0	$T\Pi$
				Group Art Unit	1614 644	20	- 0,	1
	(use as many she	ets as	necessary)	Examiner Name	Unassigned 0U	SPIPA	JS\$X	
Sheet	1	of	2	Attorney Docket Number	ALBRE-23	92	72	Ľ.

			U.S. PATENT DOCUM	MENTS	<i></i>
_		U.S. Patent Document	Name of Patentae or Applicant	Date of Publication of	Pages, Columns, Lines, Where Relevant
Examiner Initials *	Cite No. ¹	Number Kind Code ² (if known)	of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear
1.0.	1	5,858,358	June et al.	01-12-1999	
61	240				
srp 0	3 2002				
3					
TRA	DEMMARY				

			FOREIG	N PATENT DOCU	MENTS		
Examiner Cite		For	eign Patent Document	Name of Patentee	Date of Publication of	Pages, Columns, Lines, Where Relevant	
Initials*	No.1	Office ³	Number ⁴ Kind Code ⁶ (if known)	or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T ₀
\$.0.	2	wo	98 17313 .		04-30-1998		
D. O.	3	wo	94 06473		03-13-1994		
N2- 1/-	-4-	DE-	197 22 888		12-03-1998		F
D.O.	5	WO	94/29436 1		12-22-1994		
		 					
		 					
							
	 						

Examiner Signature	The	Ousp	ensli	Date Considered	03/03	/2005	
						=	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark hee if English language Translation is attached.

Please type a plus sign (+) inside this box

PTO/SB/094/08-00)

Approved for use through PRI/2002. OMB/091-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control our other contains.

Substitute for form 1449A/PTO C mplete if Known Application Number 10/049,464 INFORMATION DISCLOSURE Filing Date 06-18-2002 STATEMENT BY APPLICANT First Named Inventor HUENIG **Group Art Unit** 1614-1646 (use as many sheets as necessary) **Examiner Name** Unassigned Sheet 2 **Attorney Docket Number** ALBRE-23

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т2
D.O.	6	M.HEZAREEH ET AL., "Differential T Cell Induction of Productive HIV Replication in Samples From Patients on Prolonged Suppressive Therapy", CONFERENCE ON RETROVIRUSES AND OPPORTUNISTIC INFECTIONS, 1998, pg. 183 Vol. 5	
T.O.	7	U. HENGGE ET AL., "Randomized, Controlled Phase II Trial of Subcutaneous Interleukin-2 in Combination With Highly Active Antiretroviral Therapy (Haart) in HIV Patlents", 1998, pp. F225-F234, Vol. 12, No. 17	
J. O.	8	T-W CHUN ET AL., 'Effect of Interleukin-2 on the Pool of Latentry Infected, Resting CD4+ T Cellsin HiV-1-Infected Patients Receiving Highly Active Anti-Retroviral Therapy', NATURE MEDICINE. June 6, 1999, pp. 651-655, Vol. 5, No. 6	
	9	T-W CHUN ET AL, "Quantification of Latent Tissue Reservoirs and Total Body Viral Load in HiV-1 Infection", NATURE May 8, 1997, pp 183-188, Vol 387, No. 6629	
I.Q	10	E. Barker et al., "CD28 Costimulation Increases CD8+ Cell Suppression of HIV Replication", <u>The JOURNAL OF</u> IMMUNOLOGY, November 15, 1997, pp.51213-5131, Vol. 159, No. 10	
		·	

[asymptotic for the state of t
--

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.